Prognostic Significance of the Immunohistochemical Expression of O6-methylguanine-DNA Methyltransferase, P-glycoprotein, and Multidrug Resistance Protein-1 in Glioblastomas
Overview
Affiliations
We studied the expression of O(6)-methylguanine-DNA methyltransferase (O(6)-MGMT), P-glycoprotein (Pgp), and multidrug resistance protein-1 (MRP-1) in 23 glioblastomas using RT-PCR, methylation-specific PCR, and immunohistochemistry, and analyzed their association with overall patient survival. Univariate analysis of collected data demonstrated that the expressions of O(6)-MGMT and MRP-1 detected by immunohistochemistry, in addition to the consistent factors, including preoperative Karnofsky performance scale (KPS), radical surgery, and tumor location and extension, were significant prognostic factors for the overall survival (OS) of patients with glioblastoma, who received nimustine (ACNU)-based chemotherapy in association with surgery and radiotherapy. Among them, following multivariate analysis, preoperative KPS, radical surgery, tumor location, and the expression of O(6)-MGMT remained as significant prognostic factors. These findings suggest that immunohistochemical analysis of O(6)-MGMT in patients with glioblastoma can be a useful method to predict the effects of chemotherapy and identify alternative chemotherapeutic regimens for O(6)-MGMT-positive patients.
The impact of ATP-binding cassette transporters in the diseased brain: Context matters.
Baltira C, Aronica E, Elmquist W, Langer O, Loscher W, Sarkaria J Cell Rep Med. 2024; 5(6):101609.
PMID: 38897176 PMC: 11228798. DOI: 10.1016/j.xcrm.2024.101609.
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim S, Harford J, Moghe M, Rait A, Pirollo K, Chang E Nucleic Acids Res. 2017; 46(3):1424-1440.
PMID: 29202181 PMC: 5815062. DOI: 10.1093/nar/gkx1221.
APNG as a prognostic marker in patients with glioblastoma.
Fosmark S, Hellwege S, Dahlrot R, Jensen K, Derand H, Lohse J PLoS One. 2017; 12(6):e0178693.
PMID: 28662073 PMC: 5490991. DOI: 10.1371/journal.pone.0178693.
MGMT testing allows for personalised therapy in the temozolomide era.
Dullea A, Marignol L Tumour Biol. 2015; 37(1):87-96.
PMID: 26518768 DOI: 10.1007/s13277-015-4240-2.
Perazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M PLoS One. 2015; 10(10):e0140131.
PMID: 26447477 PMC: 4598115. DOI: 10.1371/journal.pone.0140131.